IBS-C Treatment: Diet Changes and Tenapanor What Research Shows

Irritable bowel syndrome with constipation (IBS-C) affects an estimated 15–20% of the general population, and for many patients, symptom control means juggling dietary changes, prescription drugs, and trial-and-error adjustments over years. Two recent research reviews—one from Narayana Medical College in India on diet’s role in IBS, and one from Augusta University on the FDA-approved drug tenapanor—map out what actually works, and why.

Why Food Triggers IBS Symptoms: The FODMAP Mechanism

Short-chain fermentable carbohydrates—collectively known as FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols)—sit at the center of the diet–IBS relationship. Sarvepalli and colleagues at Narayana Medical College explain the mechanism clearly: these compounds are poorly absorbed in the small intestine, so they draw water into the intestinal lumen and then become fermentation substrates for colonic bacteria. The result is increased gas production and elevated water volume in the bowel.

In a healthy gut, that extra gas and fluid passes unnoticed. In people with visceral hypersensitivity—a heightened sensitivity of gut nerves—it translates into bloating, distension, cramping, and altered bowel habits. This is why two people can eat the same meal and only one develops symptoms. It also explains why symptoms often don’t respond to simple laxatives alone: the problem is not just slow transit, but an oversensitive gut responding to bacterial fermentation products. Readers interested in how bacterial metabolites influence nerve signaling can explore how gut metabolites talk to the brain.

The Low-FODMAP Diet Works—But Not for Everyone

The Indian review consolidates multiple studies showing that restricting fermentable carbohydrates can significantly relieve IBS symptoms, and in some cases dietary restriction outperforms pharmacotherapy. That is a striking claim: changing what’s on your plate beating prescription medication for a subset of patients.

There is an important caveat, though. More than a third of individuals following a low-FODMAP diet (LFD) get no meaningful benefit. The authors frame the LFD not as a universal solution but as one tool among several dietary therapies, and they emphasize comparing long-term strategies rather than short elimination phases. Unnecessary long-term restriction also carries downsides: FODMAPs feed beneficial bacteria, and chronic restriction may reduce microbiome diversity—something covered in depth in our article on gut ecology’s impact on health and IBS.

Tenapanor: A Drug Designed Around Gut Sodium Transport

When diet and fiber fail, prescription options matter. Herekar and colleagues at Augusta University in Georgia reviewed tenapanor, a first-in-class small molecule approved by the FDA specifically for IBS-C. Its mechanism is elegant: tenapanor inhibits the sodium/hydrogen exchanger isoform 3 (NHE3), a transporter in the intestinal lining that normally reabsorbs sodium from the gut lumen. Block NHE3, and sodium stays in the bowel, pulling water with it. Stool becomes softer and transit speeds up.

What separates tenapanor from a pure laxative is its second action. The drug reduces intestinal permeability, which in animal and clinical models decreases visceral hypersensitivity—addressing the abdominal pain and discomfort that define IBS beyond simply improving stool frequency. Because tenapanor is minimally absorbed into the bloodstream (it acts locally in the gut), systemic exposure is low, which supports its tolerability profile. The authors walk through its development across Phase I, II, and III randomized clinical trials, where it demonstrated improvement in both bowel symptoms and global IBS measures. For a head-to-head comparison with another IBS-C drug, see linaclotide vs. tenapanor.

What This Means: A Stepwise, Evidence-Based Approach

One practical gap the Augusta team acknowledges: because tenapanor was approved recently, it was not yet included in major IBS treatment guidelines. Their suggested role is as a second-line option for IBS-C patients who fail first-line therapy with soluble fiber—typically psyllium. That framing gives patients and clinicians a rational sequence:

• Step 1: Soluble fiber, ideally psyllium, which holds water in stool and improves consistency without the bloating often caused by insoluble fiber.
• Step 2: Prescription secretory agents such as tenapanor, which combines a laxative-like effect with visceral pain reduction.
• In parallel: Structured dietary therapy, ideally supervised by a dietitian, with careful reintroduction after any elimination phase.

Because IBS is a disorder of gut-brain interaction with unclear, multifactorial origins, the researchers stress that treatment must address global symptoms—especially abdominal pain—not just bowel frequency. This is why drugs like tenapanor that hit both targets, and diets that reduce fermentation load, tend to outperform single-mechanism interventions.

Frequently Asked Questions

Is a low-FODMAP diet a good first step for IBS-C?

It can help, but more than a third of patients don’t benefit, so it’s best attempted with realistic expectations and ideally dietitian supervision rather than as a permanent diet.

What makes tenapanor different from regular laxatives?

Tenapanor blocks intestinal sodium absorption to retain fluid and soften stool, but it also reduces gut permeability and visceral hypersensitivity, which addresses abdominal pain—not just constipation.

Why is soluble fiber recommended before medication for IBS-C?

Soluble fiber (particularly psyllium) is the established first-line therapy because it holds water in the stool and improves consistency; drugs like tenapanor are typically reserved for when fiber alone fails.

Can IBS symptoms be caused by foods even if I’m not “allergic” to them?

Yes. FODMAPs increase colonic gas and intestinal water, and in people with visceral hypersensitivity this produces symptoms without any immune allergy or food intolerance in the classic sense.

IBS-C management has moved beyond a single pill or a single diet. The evidence now supports a layered approach: soluble fiber first, targeted pharmacotherapy like tenapanor when needed, and dietary therapy matched to the individual—because a strategy that helps two-thirds of patients still leaves a third needing something different.

Sources:
https://pubmed.ncbi.nlm.nih.gov/37846263/
https://pubmed.ncbi.nlm.nih.gov/37309470/
https://pubmed.ncbi.nlm.nih.gov/36498647/
https://pubmed.ncbi.nlm.nih.gov/36408402/
https://pubmed.ncbi.nlm.nih.gov/36235798/